Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic

Antiviral Research

Volumn 90, Issue 3, 2011, Pages 205-212

  Puzelli, Simona ^a   Facchini, Marzia ^a   Di Martino, Angela ^a   Fabiani, Concetta ^a   Lackenby, Angie ^b   Zambon, Maria ^b   Donatelli, Isabella ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Adamantanes; Antiviral resistance; Influenza; Italy; Oseltamivir; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ADAMANTANE DERIVATIVE; SIALIDASE; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG SURVEILLANCE PROGRAM; EPIDEMIC; GENE SEQUENCE; IC 50; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; ITALY; NONHUMAN; PANDEMIC; PHENOTYPE; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIRUS ISOLATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; EPIDEMICS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; ITALY; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PANDEMICS; VIRAL PROTEINS;

ORTHOMYXOVIRIDAE;

EID: 79955658470     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.04.003     Document Type: Article

References (32)

1. Aoki F.Y., Boivin G., Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir. Ther. 2007, 12:603-616.
2. Barr, I.G., Cui, L., Komadina, N., Lee, R.T., Lin, R.T., Deng, Y., Caldwell, N., Shaw, R., Maurer-Stroh, S., 2010. A new pandemic influenza A(H1N1) genetic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore. Euro Surveill. 15(42), 19692.
3. Baz M., Abed Y., Simon P., Hamelin M.E., Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J. Infect. Dis. 2010, 201(5):656-658.
4. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., Klimov A.I. Incidence of adamantane resistance among influenza A(H3N2) viruses isolated worldwide from 1994 to 2005: a cause of concern. Lancet 2005, 366:1175-1181.
5. Bright R.A., Shay D.K., Shu B., Cox N.J., Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295:891-894.
6. Campanini G., Piralla A., Rovida F., Puzelli S., Facchini M., Locatelli F., Minoli L., Percivalle E., Donatelli I., Baldanti F. Surveillance Group A. for New Influenza/H1N1v Investigation in Italy, First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection. J. Clin. Virol. 2010, 48:220-222.
7. DC C. Influenza activity - United States and worldwide, May 18--September 19, 7. Morb. Mortal. Wkly. Report 2008, 57:1046-1049.
8. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., Gubareva L.V., Xu X., Bridges C.B., Uyeki T.M. Emergence of a novel swine-origin influenza A(H1N1) virus in humans. N. Engl. J. Med. 2009, 360:2605-2615.
9. Deyde V.M., Okomo-Adhiambo M., Sheu T.G., Wallis T.R., Fry A., Dharan N., Klimov A.I., Gubareva L.V. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antivir. Res. 2009, 81:16-24.
10. Deyde V.M., Sheu T.G., Trujillo A.A., Okomo-Adhiambo M., Garten R., Klimov A.I., Gubareva L.V. Detection of molecular markers of drug resistance in 2009 pandemic Influenza (H1N1) viruses by pyrosequencing. Antimicrob. Agents Chemother. 2010, 54(3):1102-1110.
11. European Centre for Disease Prevention and Control special report. 2010. The 2009 A(H1N1) pandemic in Europe. A review of the experience. ECDC. Available from: .
12. Ferraris O., Kessler N., Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antivir. Res. 2005, 68:43-48.
13. Ferraris O., Lina B. Mutation of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 2008, 41:13-19.
14. Garten R.J., Davis C.T., Russel C.A., Shu B., Lindstrom S., Balish A., Sessions W.M., Xu X., Skepner E., Deyde V., Okomo-Adhiambo M., Gubareva L., Barnes J., Smith C.B., Emery S.L., Hillman M.J., Rivailler P., Smagala J., de Graaf M., Burke D.F., Fouchier R.A.M., Pappas C., Alpuche-Aranda C.M., López-Gatell H., Olivera H., López I., Myers C.A., Faix D., Blair P.J., Yu C., Keene K.M., Dotson P.D., Boxrud D., Sambol A.R., Abid S.H., George K.S., Bannerman T., Moore A.L., Stringer D.J., Blevins P., Demmler-Harrison G.J., Ginsberg M., Kriner P., Waterman S., Smole S., Guevara H.F., Belongia E.A., Clark P.A., Beatrice S.T., Donis R., Katz J., Finelli L., Bridges C.B., Shaw M., Jernigan D.B., Uyeki T.M., Smith D.J., Klimov A.I., Cox N.J. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937):197-201.
15. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 2001, 183(4):523-531.
16. Hauge S.H., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 2009, 15(2):155-162.
17. Hayden F.G., Belshe R.B., Clover R.D., Hay A.J., Oakes M.G., Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 1989, 321:1696-1702.
18. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., Zambon M.C. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008, 13:8026.
19. Mast E.E., Harmon M.W., Gravenstein S., Wu S.P., Arden N.H., Circo R., Tyszka G., Kendal A.P., Davis J.P. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am. J. Epidemiol. 1991, 134:988-997.
20. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., Zambon M. Neuraminidase sequence analysis and susceptilities of influenza virus clinical isolates to Zanamivir and Oseltamivir. Antimicrob. Agents Chemother. 2003, 47:2264-2272.
21. Meijer A., Lackenby A., Hay A., Zambon M. Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. Euro. Surveill. 2007, 12(4):698.
22. Meijer A., Lackenby A., Hungnes O., Lina B., van-der-Werf S., Schweiger B., Opp M., Paget J., van-de-Kassteele J., Hay A., Zambon M. European Influenza Surveillance Scheme. Oseltamivir-resistant influenza A(H1N1) viruses, Europe 2007-2008 influenza season. Emerg. Infect. Dis. 2009, 15(4):552-560.
23. Mishin V.P., Hayden F.G., Gubareva L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 2005, 49(11):4515-4520.
24. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., Zambon M. Detection of influenza viruses resistant to Neuraminidase Inhibitors in global surveillance during the first 3years of their use. Antimicrob. Agents Chemother. 2006, 50:2395-2402.
25. Mould J.A., Drury J.E., Frings S.M., Kaupp U.B., Pekosz A., Lamb R.A., Pinto L.H. Permeation and activation of the M2 ion channel of influenza A virus. J. Biol. Chem. 2000, 275:31038-31050.
26. Okomo-Adhiamobo M., Nguyen H.T., Sleeman K., Sheu T.G., Deyde V.M., Garten R.J., Xu X., Shaw M.W., Klimov A.I., Gubareva L.V. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antivir. Res. 2010, 85:381-388.
27. Pizzorno A., Bouhy X., Abed Y., Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 2011, 203(1):25-31.
28. Puzelli S., Frezza F., Fabiani C., Ansaldi F., Campitelli L., Lin Y.P., Gregory V., Bennett M., D'Agaro P., Campello C., Crovari P., Hay A., Donatelli I. Changes in the hemagglutinins and neuraminidases of human influenza B viruses isolated in Italy during the 2001-02, 2002-03, and 2003-04 seasons. J. Med. Virol. 2004, 74(4):629-640.
29. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide in 2004-2008. Antimicrob. Agents Chemother. 2008, 52(9):3284-3292.
30. Stoner T.D., Krauss S., DuBois R.M., Negovetich N.J., Stallknecht D.E., Senne D.A., Gramer M.R., Swafford S., DeLiberto T., Govorkova E.A., Webster R.G. Antiviral susceptibility of avian and Swine influenza virus of N1 neuraminidase subtype. J. Virol. 2010, 84(19):9800-9809.
31. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breschkin J.L., Zambon M., Hayden F.G. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 2003, 41(2):742-750.
32. World Health Organization (WHO)., 2010. Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January; Wkly Epidemiol, Rec. 85, 37-48. http://www.who.int/wer/2010/wer8506/en/index.html.